The North American Non-Knowledge Based Clinical Decision Support System (CDSS) market report defines and segments the market in North America with analysis and forecast of revenue. The Knowledge-based/evidence-based CDSS market in North America is expected to reach around $20.0 million by 2018, at a CAGR of 2.1% from 2013 to 2018.
Browse through the TOC of the North American non-knowledge based clinical decision support system (CDSS) market, to get an idea of the in-depth analysis provided. This also provides a glimpse of the market segmentation, and is supported by various tables and figures.
The non-knowledge based CDSS uses a form of artificial intelligence called machine learning, which makes decisions based on historic experience and finds patterns in clinical data. The system analyzes patterns found in patient data, which eliminates the need for writing rules and the need for expert advice on any particular issue. The clinical decision support system (CDSS) was introduced as an efficient solution that can offer personalized medicine at the point of care. However, this system cannot elaborate the reasons behind selection of data, which might lead to medication errors. Due to this, most clinicians do not use this system for decision-making. Hence, the demand for such models is likely to decrease in coming years. Furthermore, in comparison to knowledge-based CDSS, non-knowledge-based models perform study on limited diseases at one time. This would further restrict the prospects of this market. The U.S. is currently facing a major challenge in countering the growing healthcare costs. The growing healthcare costs have pressurized the healthcare industry to provide optimum solutions. Therefore, the rate of adoption of healthcare IT solutions, mainly, CDSS, has increased which ultimately helps the non-knowledge-based CDSS market to grow. Besides, the growing...
Please join StudyMode to read the full document